Search Results
Jul 23, 2026, 08:32 ET Pusan National University: Beyond Antibiotics--A Paradigm Shift Toward Bacteria-Control-Centric Therapies
creating a targeted delivery platform called PMB@TimP EVs. Acting as a "Trojan-horse drug delivery system," the vesicles delivered the antibiotic directly to bacteria by making the bacterial membrane easier for the drug to penetrate.Further analysis showed that PMB@TimP EVs enhanced bacterial killing,
More news about: Pusan National University
Jul 23, 2026, 08:30 ET Halozyme to Report Second Quarter 2026 Financial and Operating Results
company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected
More news about: Halozyme Therapeutics, Inc.
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
approval from the U.S. Food and Drug Administration (FDA) in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients
More news about: Johnson & Johnson
Jul 23, 2026, 08:05 ET Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
at launch. As of July 1st, both brands are Preferred on Cigna Advantage, Performance, and Legacy Performance commercial pharmacy benefit drug lists. Additionally, on September 1st, both brands will be Preferred on the Cigna commercial medical benefit. Through AccordCares, eligible
More news about: Accord BioPharma
Jul 23, 2026, 08:00 ET Evoworks Bio Selected for BARDA-Backed VANGUARD Program to Demonstrate Rapid, Scalable Production of Critical Biologics
reduction."Chosen from more than 170 applicants, the VANGUARD awardees represent the most promising innovations in life science tools for bioanalysis, diagnostics, drug discovery, and biomanufacturing that can play a critical role in U.S. health security. Over the 6-month program, participants will work closely with
More news about: Kemp Proteins
Jul 23, 2026, 08:00 ET Precision Diabetes and Nagase Diagnostics Announce Exclusive U.S. Commercialization Partnership for Lucica® Glycated Albumin-L, the Only FDA-Cleared Assay Specifically Measured Glycated Albumin in the United States
announced an exclusive U.S. commercialization partnership for the Lucica®GlycatedAlbumin(GA)-Lassay (510(k) No. K170147), the only assay with U.S. Food and Drug Administration (FDA) 510(k) clearance in the United States that is specifically intended to measure glycated albumin.
More news about: Precision Diabetes, Inc.
Jul 23, 2026, 07:03 ET C & C Heating & Air Conditioning urges Michigan homeowners to prepare for the next heat wave
all makes and models of heating and cooling equipment. Their technicians are highly trained and qualified and undergo annual background checks, random drug testing, extensive technical and customer service training and are North American Technician Excellence (NATE) certified. Services include HVAC maintenance
More news about: C & C Heating & Air Conditioning
Jul 23, 2026, 07:00 ET Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases— as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around
More news about: Insmed Incorporated
Jul 23, 2026, 06:45 ET Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned,
More news about: Eli Lilly and Company
Jul 23, 2026, 06:00 ET West Reports Second-Quarter 2026 Results
Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000
More news about: West Pharmaceutical Services, Inc.
Jul 23, 2026, 03:33 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
Orexin signaling and sleep-wake regulation. Front Cell Neurosci. 2022;16:812359.U.S. Food and Drug Administration. Fast Track Designation Requests.U.S. Food and Drug Administration. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. CONTACT:H.
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:29 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
Orexin signaling and sleep-wake regulation. Front Cell Neurosci. 2022;16:812359.U.S. Food and Drug Administration. Fast Track Designation Requests.U.S. Food and Drug Administration. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. CONTACT:H.
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:27 ET Nordic Capital announces agreement to sell ArisGlobal to Dassault Systèmes, following its transformation into a scaled and AI-enabled life sciences platform
team.The migration to a modern, cloud-native architecture created the foundation for ArisGlobal to become an early leader in the application of AI to drug safety. A key milestone was the development and launch of NavaX, ArisGlobal's generative AI solution for safety case processing, which automates and
More news about: Nordic Capital
Jul 23, 2026, 03:24 ET Nordic Capital announces agreement to sell ArisGlobal to Dassault Systèmes, following its transformation into a scaled and AI-enabled life sciences platform
team.The migration to a modern, cloud-native architecture created the foundation for ArisGlobal to become an early leader in the application of AI to drug safety. A key milestone was the development and launch of NavaX, ArisGlobal's generative AI solution for safety case processing, which automates and
More news about: Nordic Capital
Jul 23, 2026, 03:00 ET Can an Aging America Escape the Nursing Home Default? "All Access hosted by Andy Garcia" Features Northland PACE Senior Care Services
collaboration among disparate healthcare entities has forced families into costly, inefficient choices that accelerate institutionalization. Furthermore, rising drug prices and the skyrocketing costs of standalone personal care services continuously drain household resources. This systemic friction highlights the
More news about: All Access
Jul 23, 2026, 02:08 ET Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
all of which are included in China's National Reimbursement Drug List (NRDL).Cipepofol Injection, an innovative intravenous anesthetic with independent intellectual property rights, received marketing approval from the U.S. Food and Drug Administration (FDA) in late May of this year. It is the first
More news about: Haisco Pharmaceutical Group Co., Ltd.
Jul 22, 2026, 20:55 ET Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases
antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery platform), Modalities-on-Demand® (a
More news about: Nona Biosciences
Jul 22, 2026, 20:10 ET Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides,
More news about: Ascletis Pharma Inc.
Jul 22, 2026, 20:10 ET 歌禮宣佈將在第62屆歐洲糖尿病研究協會（EASD）年會上以口頭討論形式匯報ASC36_35 FDC減重效果優於eloralintide聯合tirzepatide的臨床前數據
歌禮製藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥
More news about: 歌禮製藥有限公司
Jul 22, 2026, 19:03 ET Samsung Biologics Reports Second Quarter 2026 Financial Results
Venture Investment. In May, the fund invested in Cartography Biosciences to support global collaboration in genomics-based antigen discovery and oncology drug development, and the following month, an additional investment worth KRW 200 billion was made to create the third Life Science Fund.Samsung
More news about: Samsung Biologics
Jul 22, 2026, 18:45 ET ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236,
More news about: THE ROSEN LAW FIRM, P. A.
Jul 22, 2026, 16:05 ET Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation,
More news about: Nuvation Bio, Inc.
Jul 22, 2026, 16:05 ET Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
More news about: Azenta
Jul 22, 2026, 16:00 ET Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
efficacy data, along with disclosures regarding communications with the FDA.Aardvark had emphasized that ARD-101 represented a "first-in-class" drug and that, "through alignment with the FDA," it started HERO patients 13 years and older, moved to dosing patients 10 years and older, and intended to
More news about: Hagens Berman Sobol Shapiro LLP
Jul 22, 2026, 13:58 ET Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced
More news about: GSK plc